Evoke Pharma, Inc.

The global gastroparesis drugs market is projected to grow by USD 1.42 billion from 2024 to 2028, with a CAGR of 3.69%. Key segments include drug class, disease type, and geography. Prokinetic drugs like metoclopramide and domperidone are significant for managing symptoms. New drugs under development aim to improve treatment outcomes.

The Nasal Drug Delivery Technology Market is projected to grow from USD 4.4 billion in 2024 to USD 7.8 billion by 2031, driven by non-invasive drug administration, technological advancements, and rising respiratory disease prevalence.

The Nasal Drug Delivery Technology Market is projected to grow from USD 4.4 billion in 2024 to USD 7.8 billion by 2031, driven by non-invasive drug administration, technological advancements, and rising respiratory disease prevalence.

Evoke Pharma reaffirms commitment to improving diabetic gastroparesis treatment with Gimoti nasal spray after FDA's rejection of Vanda Pharmaceuticals' Tradipitant.